ES2161915T3 - Conjugados monofuncionales y/o polifuncionales de la polilisina. - Google Patents
Conjugados monofuncionales y/o polifuncionales de la polilisina.Info
- Publication number
- ES2161915T3 ES2161915T3 ES95940329T ES95940329T ES2161915T3 ES 2161915 T3 ES2161915 T3 ES 2161915T3 ES 95940329 T ES95940329 T ES 95940329T ES 95940329 T ES95940329 T ES 95940329T ES 2161915 T3 ES2161915 T3 ES 2161915T3
- Authority
- ES
- Spain
- Prior art keywords
- polylisine
- conjugates
- monofunctional
- polyfunctional
- invention refers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polyamides (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9413861A FR2727117A1 (fr) | 1994-11-18 | 1994-11-18 | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2161915T3 true ES2161915T3 (es) | 2001-12-16 |
Family
ID=9468953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95940329T Expired - Lifetime ES2161915T3 (es) | 1994-11-18 | 1995-11-17 | Conjugados monofuncionales y/o polifuncionales de la polilisina. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6114388A (enExample) |
| EP (1) | EP0792167B1 (enExample) |
| JP (1) | JP4128618B2 (enExample) |
| AT (1) | ATE202487T1 (enExample) |
| AU (1) | AU694825B2 (enExample) |
| CA (1) | CA2205557C (enExample) |
| DE (1) | DE69521521T2 (enExample) |
| DK (1) | DK0792167T3 (enExample) |
| ES (1) | ES2161915T3 (enExample) |
| FR (1) | FR2727117A1 (enExample) |
| GR (1) | GR3036710T3 (enExample) |
| NZ (1) | NZ297040A (enExample) |
| PT (1) | PT792167E (enExample) |
| WO (1) | WO1996015810A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO104396A0 (en) * | 1996-07-17 | 1996-08-08 | Biomolecular Research Institute Limited | Antiviral linear polymers |
| DE69835201T2 (de) | 1997-04-18 | 2007-06-14 | Novartis Ag | Neoglycoproteine |
| FR2763853B1 (fr) * | 1997-05-28 | 2000-01-07 | Oreal | Association d'un retinoide avec un polymere polyamine |
| DE19732139C2 (de) * | 1997-07-25 | 2002-10-10 | Max Planck Gesellschaft | Mesomorphe Komplexe aus Vitamin A-Säure und kationischen Polyelektrolyten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen |
| FR2773808B1 (fr) * | 1998-01-20 | 2000-05-05 | Sagebo | Composes susceptibles de pieger les ions metalliques, leur procede d'obtention et leur utilisation |
| US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
| US6686446B2 (en) * | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| GB9811059D0 (en) * | 1998-05-23 | 1998-07-22 | Univ Strathclyde | Polyamino acid vesicles |
| DE69923322T2 (de) * | 1998-07-30 | 2005-12-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung |
| CA2372526A1 (en) * | 1999-05-10 | 2000-11-16 | Michael D. Wyrsta | Methods and compositions for controlled polypeptide synthesis |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| FR2842422B1 (fr) * | 2002-07-16 | 2006-06-30 | Univ Aix Marseille Ii | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations |
| CA2759572A1 (en) * | 2002-08-08 | 2004-02-19 | Baylor College Of Medicine | Isolation and identification of t cells |
| WO2004020673A1 (en) * | 2002-08-28 | 2004-03-11 | Millipore Corporation | Compositions of solution for sequencing reaction clean-up |
| US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
| ATE499104T1 (de) * | 2005-03-24 | 2011-03-15 | Univ Emory | Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns |
| US7473687B2 (en) * | 2005-03-24 | 2009-01-06 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
| FR2886153B1 (fr) * | 2005-05-27 | 2009-04-10 | Gemac Sa | Composition destinee au traitement de la sclerose en plaques |
| CA2651328A1 (en) * | 2006-05-05 | 2007-11-15 | Opexa Therapeutics | T-cell vaccine |
| FR2905868B1 (fr) * | 2006-09-18 | 2012-12-21 | Gemac | Composition destinee au traitement de la sclerose laterale amyotrophique |
| EP2107913B1 (en) | 2006-12-22 | 2012-02-15 | Croma-Pharma Gesellschaft m.b.H. | Use of thiolated polysaccharides for tissue augmentation |
| FR2913335B1 (fr) | 2007-03-06 | 2009-06-05 | Michel Geffard | Utilisation de conjugues d'acides gras et de poly-l-lysine pour lutter contre des microorganismes pathogenes. |
| EP2085082A1 (en) * | 2008-01-29 | 2009-08-05 | Nutromnia S.R.L. | Treatment of cognitive decline |
| SG193926A1 (en) * | 2011-04-12 | 2013-11-29 | Nestec Sa | Nutritional compositions including branched chain fatty acids and methods of using same |
| PL3116887T3 (pl) | 2014-03-13 | 2021-09-06 | Universität Basel | Ligandy węglowodanowe, które wiążą się z przeciwciałami igm przeciwko glikoproteinie związanej z mieliną |
| FR3030524B1 (fr) * | 2014-12-17 | 2017-01-20 | Hydro-Fill | Utilisation de pll pour ameliorer la stabilite de molecules en solution |
| CN108026134A (zh) | 2015-09-16 | 2018-05-11 | 巴塞尔大学 | 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体 |
| FR3048616B1 (fr) * | 2016-03-14 | 2018-04-06 | Polyneuros | Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique |
| FR3122571B1 (fr) * | 2021-05-10 | 2023-05-12 | Hydro Fill Tech | Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles |
| FR3122573B1 (fr) * | 2021-05-10 | 2024-03-29 | Hydro Fill Tech | Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1979000515A1 (en) * | 1978-01-16 | 1979-08-09 | Univ Boston | Method of effecting cellular uptake of molecules |
| DE3546150A1 (de) * | 1985-06-24 | 1987-01-22 | Hoechst Ag | Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung |
| GB9004538D0 (en) * | 1990-02-28 | 1990-04-25 | Offord Robin E | Chemical compounds |
| AU1674292A (en) * | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
| AU4534593A (en) * | 1992-06-12 | 1994-01-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| FR2705234B1 (fr) * | 1993-05-19 | 1995-08-04 | Geffard Michel | Utilisation de molécules reconnues par des autoanticorps de sérums humains pour le diagnostic ou le traitement du SIDA. |
-
1994
- 1994-11-18 FR FR9413861A patent/FR2727117A1/fr active Granted
-
1995
- 1995-11-17 CA CA002205557A patent/CA2205557C/en not_active Expired - Lifetime
- 1995-11-17 WO PCT/FR1995/001517 patent/WO1996015810A1/fr not_active Ceased
- 1995-11-17 JP JP51662296A patent/JP4128618B2/ja not_active Expired - Fee Related
- 1995-11-17 DE DE69521521T patent/DE69521521T2/de not_active Expired - Lifetime
- 1995-11-17 EP EP95940329A patent/EP0792167B1/fr not_active Expired - Lifetime
- 1995-11-17 US US08/836,199 patent/US6114388A/en not_active Expired - Lifetime
- 1995-11-17 NZ NZ297040A patent/NZ297040A/xx unknown
- 1995-11-17 AT AT95940329T patent/ATE202487T1/de not_active IP Right Cessation
- 1995-11-17 DK DK95940329T patent/DK0792167T3/da active
- 1995-11-17 ES ES95940329T patent/ES2161915T3/es not_active Expired - Lifetime
- 1995-11-17 PT PT95940329T patent/PT792167E/pt unknown
- 1995-11-17 AU AU41811/96A patent/AU694825B2/en not_active Ceased
-
2001
- 2001-09-26 GR GR20010401567T patent/GR3036710T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10511643A (ja) | 1998-11-10 |
| PT792167E (pt) | 2001-12-28 |
| US6114388A (en) | 2000-09-05 |
| NZ297040A (en) | 1999-05-28 |
| CA2205557C (en) | 2008-07-15 |
| DK0792167T3 (da) | 2001-10-29 |
| CA2205557A1 (en) | 1996-05-30 |
| AU4181196A (en) | 1996-06-17 |
| FR2727117B1 (enExample) | 1997-02-21 |
| WO1996015810A1 (fr) | 1996-05-30 |
| EP0792167A1 (fr) | 1997-09-03 |
| GR3036710T3 (en) | 2001-12-31 |
| AU694825B2 (en) | 1998-07-30 |
| FR2727117A1 (fr) | 1996-05-24 |
| JP4128618B2 (ja) | 2008-07-30 |
| ATE202487T1 (de) | 2001-07-15 |
| EP0792167B1 (fr) | 2001-06-27 |
| DE69521521T2 (de) | 2002-04-25 |
| DE69521521D1 (de) | 2001-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI952920L (fi) | 7-halogeeni- ja 7beta,8beta-metano-taksolit, niiden antineoplastinen käyttö ja niitä sisältävät farmaseuttiset koostumukset | |
| CA2205557A1 (en) | Monofunctional and/or polyfunctional polylysine conjugates | |
| DK0960107T3 (da) | 6-Thiosubstituerede paclitaxeler | |
| ATE231872T1 (de) | Thiazolopyrimidinderivate | |
| MX9102353A (es) | N,o-sulfados de heparosanos, su procedimiento de preparacion y las composiciones farmaceuticas que contienen. | |
| DE69632256D1 (de) | Antivirale proteine, dafür kodierende dna, und deren verwendung | |
| YU51095A (sh) | Benzokazolil - i benzotiazolil-oksazo lidinoni | |
| BR9811121A (pt) | Produto, composição farmacêutica, e uso de um produto | |
| EE05074B1 (et) | Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid | |
| PT1181027E (pt) | Composicao dietetica ou farmaceutica para utilizacao na prevencao ou tratamento de hiperoxaluria | |
| BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| ES2181744T3 (es) | Hidratos de paclitaxel cristalinos. | |
| DE3887014D1 (de) | Nukleoside, ihre Herstellung und pharmazeutische Zusammenstellungen. | |
| PT767172E (pt) | 8-arilalquil e 8-aril-heteroalquil-5, 11-di-hidro-6h-dipirido¬3,2-b:2' 3'-e| ¬1,4|diazepinas e a sua utilizacao na prevencao do tratamento da infeccao po hiv | |
| SE9904377D0 (sv) | Pharmaceutical combinations | |
| NO990440L (no) | Preparat som innbefatter mupirocin og klorheksidin | |
| NO308030B1 (no) | Kolkisinderivater og deres terapeutiske anvendelse | |
| ES2132556T3 (es) | Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen. | |
| HRP20070431T3 (en) | Use of nail restructuring compositions for topical application in onychoschizia | |
| DE60021413D1 (de) | Anti-virale zusammensetzung enthaltend ein palmaria palmata extrakt | |
| BR0012184B1 (pt) | compostos derivados de indol, formulação farmacêutica, e, composição e uso dos compostos na fabricação de medicamentos | |
| EE03996B1 (et) | Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine | |
| DE69016284D1 (de) | Antibiotikum GE 22270, Faktoren A1,A2,A3 und H. | |
| DK0451486T3 (da) | Antibiotikum GE 2270 faktorer B1, B2, C1, C2, D1, D2, E og T | |
| GR1003490B (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 792167 Country of ref document: ES |